ClinicalTrials.gg
RecruitingNCT07516444TRIVITAUpdated Nov 10, 2026

VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)

An interventional study of Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System and Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE System in Tricuspid Valve Regurgitation, Tricuspid Valve Disease and Cardiovascular Diseases (CVD), sponsored by VDyne, Inc.. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by VDyne, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 10, 2026Enrollment updatedPrimary outcomes revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Tricuspid Valve Insufficiency with a site in United States — 27 open to participants now, 36 under way, none of them phase 3. Tricuspid Valve Insufficiency · United States.

Planned enrollment
9th of 42
520 · median 63
Started
2026
with 9 others
No phase
39 of 60
18 open now
Primary completion
2029-06
later than 28 of 35 live
Registered
55th of 60
by date

Among the 60 studies in Tricuspid Valve Insufficiency with a site in United States, this one is the 9th largest by planned enrollment of the 42 interventional ones that give a count, is one of 10 that started in 2026, is one of 39 with no phase, reaches primary completion later than 28 of the 35 other live ones, and was the 55th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

27 of the 60 studies in Tricuspid Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Tricuspid Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

Pivotal trial to evaluate the safety and clinical efficacy of the VDyne TriNova System for the treatment of symptomatic severe or greater tricuspid regurgitation.

Read the detailed description

The clinical trial is a prospective, multi-center, randomized controlled pivotal trial to evaluate the safety and effectiveness of the VDyne TriNova Transcatheter Tricuspid Valve Replacement (TTVR) System compared to Edwards EVOQUE TTVR System in symptomatic patients with severe or greater tricuspid regurgitation. Subjects will be followed at discharge, 30 days, 3 months, 6 months and annually through 5 years.

03

Conditions studied

  • Tricuspid Valve Regurgitation
  • Tricuspid Valve Disease
  • Cardiovascular Diseases (CVD)
  • Heart Valve Diseases
  • Tricuspid Valve Insufficiency
  • Severe Heart Valve Disease
  • Randomized Controlled Trial (RCT)
  • Symptomatic Tricuspid Regurgitation

Keywords

  • VDyne
  • TRIVITA
  • TRIVITA Pivotal
  • Tricuspid Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old
  • Subject is willing and able to comply with all study evaluations and provide consent
  • Subject must agree not to participate in any other clinical trial for a period of one year following index procedure
  • (NYHA) Functional Class II, III, or IV and ambulatory
  • At least severe symptomatic tricuspid regurgitation.
  • Despite adequate and Optimized Medical Therapy (OMT), subject has signs and symptoms from TR, or prior heart failure hospitalization from TR
  • Heart team determines that the subject is appropriate for transcatheter tricuspid valve replacement
  • Functional and/or degenerative TR graded as at least severe

Exclusion criteria

Exclusion Criteria:

  • Subject unable or unwilling to comply with study required testing and follow-up visits
  • Subject is currently participating in another clinical trial (drug, biologic, or device) that has not yet completed its primary endpoint or is likely to interfere with this study
  • Pregnant, lactating subjects, and /or those who plan pregnancy in the period up to one year following index procedure.
  • Known or to procedural or post-procedural medications (e.g., contrast solution, anticoagulation, etc.) which cannot be adequately managed medically
  • ≤12 months due to non-cardiac comorbidities
  • Current IV Drug user (must be free from drug abuse for ≥1 year)
  • Subject unable or unwilling to provide written, before study enrollment
  • Tricuspid valve anatomy (cardiac and vascular) that is not suitable for the VDyne System
  • Hypersensitivity to metals (such as nickel or titanium)
  • Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne valve (e.g., valve replacement, edge to edge repair, etc.)
  • Severe valvular heart disease using established echocardiographic criteria requiring intervention other than the tricuspid valve
  • Known significant intracardiac shunt (e.g., septal defect).
  • Cerebrovascular accident (stroke, ) within 90 days of treatment procedure
  • Severe lung disease (severe ) or continuous use of home oxygen or oral
  • Acute myocardial infarction (AMI) within 30 days of SSC determination of eligibility
  • Leukopenia, chronic anemia ( \< 9 g/dL), current thrombocytopenia ( \<70/mcL), history of bleeding diathesis, or coagulopathy
  • Unwilling to receive blood products
  • Deep vein thrombosis and/or pulmonary embolism in the last 6-months
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Randomized cohort VDyne TriNova TTVR

    Transcatheter tricuspid valve replacement with VDyne TriNova System in patients with severe or greater tricuspid regurgitation.

    Device: Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System

  • Active comparator
    Randomized cohort Edwards EVOQUE TTVR

    Transcatheter tricuspid valve replacement with Edwards EVOQUE System in patients with severe or greater tricuspid regurgitation.

    Device: Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE System

  • Experimental
    Single Arm Registry

    Transcatheter tricuspid valve replacement with VDyne TriNova System in patients with severe or greater tricuspid regurgitation who are deemed ineligible to be treated with Active Comparator EVOQUE device.

    Device: Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System

Interventions

  • DeviceTranscatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System

    Subjects will undergo TTVR procedure with VDyne TriNova device and will continue to be managed on Optimal Medical Therapy (OMT).

    Also known as: Transcatheter Tricuspid Valve Replacement

  • DeviceTranscatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE System

    Subjects will undergo TTVR procedure with Edwards EVOQUE device and will continue to be managed on Optimal Medical Therapy (OMT).

    Also known as: Transcatheter Tricuspid Valve Replacement

06

What researchers measure

Primary outcomes

  1. Composite of major adverse events (MAEs)

    * Cardiovascular mortality * Myocardial infarction * All stroke * New need for renal replacement therapy * Severe bleeding * Non-elective tricuspid valve re-intervention * Major access site and vascular complications * Major cardiac structural complications * Device-related pulmonary embolism * New arrhythmia or conduction disorder requiring permanent pacing

    Time frame: 30 days post-procedure

  2. Composite of all-cause mortality, heart failure hospitalization, or non-elective tricuspid valve reintervention

    Time frame: 12 months post-procedure

  3. Change in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Quality of Life KCCQ questionnaire is a measure of health-related quality of life. It is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life related to Heart Failure. From 23-items, the Overall Summary Score (OSS) will be calculated. In the OSS, each of the 23 items are converted onto a 0 to 100 scale using this formula: (Raw score - Minimum Raw Score)/(Maximum Raw Score - Minimum Raw Score) \* 100. Then these are averaged across the 23 items. A score of 100 (the maximum score) would indicate maximum quality of life relating to heart failure and a score of 0 (scale minimum) would indicate the worst possible quality of life relating to heart failure, with higher scores generally indicating higher quality of life.

    Time frame: 12 months post-procedure

  4. Change in Quality of Life (QOL) as measured by New York Heart Association (NYHA)

    New York Heart Association (NYHA) Classification at 6 months. The New York Heart Association (NYHA) Classification provides a way of classifying the extent of heart failure by classifying patients in one of four categories based on their limitations during physical activity and in degree of shortness of breath and or angina pain. Class I is the least severe and Class IV is the most severe. The classes are: Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances. Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

    Time frame: 12 months post-procedure

Secondary outcomes

  1. All-Cause Mortality

    Total number of deaths from any cause

    Time frame: At 12 months and 24 months

  2. RVAD implantation or heart transplant

    Total number of patients requiring Right Ventricular Assist Device (RVAD) implantation or heart transplant

    Time frame: At 12 months and 24 months

  3. Tricuspid valve surgical or percutaneous intervention

    Total number of non-elective tricuspid valve re-interventions

    Time frame: At 12 months and 24 months

  4. Heart failure hospitalizations

    Total number of patients with at least one hospital admission due to heart failure

    Time frame: At 12 months and 24 months

  5. Change in 6-Minute Walk Distance (6MWD)

    Functional status improvement, as measured by 6-Minute Walk Test total distance walked. The 6-Minute Walk Test (6MWT) is a test that measures the total distance an individual can walk on a flat, hard surface in 6 minutes. It is commonly used to evaluate functional exercise capacity in patients with conditions including heart failure. The minimum score possible is 0, which would represent an inability to walk any distance. There is no maximum score, as a patient could theoretically walk any distance in 6 minutes though 800 meters considered the top reference range, which is what would be expected by elite athletes. Higher score indicate greater higher exercise capacity and lower scores indicate lower exercise capacity.

    Time frame: At 12 months and 24 months

  6. Change in Echocardiographic Tricuspid Regurgitation (TR) grade from baseline using TransThoracic Echocardiogram (TTE)

    Change in Tricuspid Regurgitation (TR) grade from baseline is measured. A 5-tier grading scheme will be used: mild, moderate, severe, massive and torrential. The change in TR grade is assessed using TransThoracic Echocardiogram (TTE) imaging.

    Time frame: At 6 months, 12 months and 24 months post-implant compared to baseline

  7. Change in Quality of Life (QOL) as measured by New York Heart Association (NYHA)

    New York Heart Association (NYHA) Classification at 6 months. The New York Heart Association (NYHA) Classification provides a way of classifying the extent of heart failure by classifying patients in one of four categories based on their limitations during physical activity and in degree of shortness of breath and or angina pain. Class I is the least severe and Class IV is the most severe. The classes are: Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances. Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

    Time frame: 12 months post-procedure

  8. Change in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Quality of Life KCCQ questionnaire is a measure of health-related quality of life. It is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life related to Heart Failure. From 23-items, the Overall Summary Score (OSS) will be calculated. In the OSS, each of the 23 items are converted onto a 0 to 100 scale using this formula: (Raw score - Minimum Raw Score)/(Maximum Raw Score - Minimum Raw Score) \* 100. Then these are averaged across the 23 items. A score of 100 (the maximum score) would indicate maximum quality of life relating to heart failure and a score of 0 (scale minimum) would indicate the worst possible quality of life relating to heart failure, with higher scores generally indicating higher quality of life.

    Time frame: 12 months post-procedure

07

Study locations

12 of 12 sites recruiting
08

References and documents

Publications

  • Azami P, Hosseinpour A, Kamalpour J, Rajabi F, Razeghian-Jahromi I, Farhangdoost S, Vafa RG, Bagheri G. Efficacy and Safety of Transcatheter Tricuspid Valve Replacement in Patients With Moderate to Severe Tricuspid Regurgitation: A Systematic Review and Meta-Analysis on Clinical Outcomes and Echocardiographic Indices. Health Sci Rep. 2025 Jun 23;8(6):e70950. doi: 10.1002/hsr2.70950. eCollection 2025 Jun. PubMed 40551865 ↗
  • Fam NP, von Bardeleben RS, Hensey M, Kodali SK, Smith RL, Hausleiter J, Ong G, Boone R, Ruf T, George I, Szerlip M, Nabauer M, Ali FM, Moss R, Bapat V, Schnitzler K, Kreidel F, Ye J, Deva DP, Mack MJ, Grayburn PA, Peterson MD, Leon MB, Hahn RT, Webb JG. Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System: A Multicenter, Observational, First-in-Human Experience. JACC Cardiovasc Interv. 2021 Mar 8;14(5):501-511. doi: 10.1016/j.jcin.2020.11.045. Epub 2021 Feb 10. PubMed 33582084 ↗
  • Hahn RT, Makkar R, Thourani VH, Makar M, Sharma RP, Haeffele C, Davidson CJ, Narang A, O'Neill B, Lee J, Yadav P, Zahr F, Chadderdon S, Eleid M, Pislaru S, Smith R, Szerlip M, Whisenant B, Sekaran NK, Garcia S, Stewart-Dehner T, Thiele H, Kipperman R, Koulogiannis K, Lim DS, Fowler D, Kapadia S, Harb SC, Grayburn PA, Sannino A, Mack MJ, Leon MB, Lurz P, Kodali SK; TRISCEND II Trial Investigators. Transcatheter Valve Replacement in Severe Tricuspid Regurgitation. N Engl J Med. 2025 Jan 9;392(2):115-126. doi: 10.1056/NEJMoa2401918. Epub 2024 Oct 30. PubMed 39475399 ↗
  • Arnold SV, Hahn RT, Thourani VH, Makkar R, Makar M, Sharma RP, Haeffele C, Davidson CJ, Narang A, O'Neill B, Lee J, Yadav P, Zahr F, Chadderdon S, Eleid M, Pislaru S, Smith R, Szerlip M, Whisenant B, Sekaran N, Garcia S, Stewart-Dehner T, Grayburn PA, Sannino A, Snyder C, Zhang Y, Mack MJ, Leon MB, Lurz P, Kodali S, Cohen DJ; TRISCEND II Pivotal Trial Investigators. Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial. J Am Coll Cardiol. 2025 Jan 28;85(3):206-216. doi: 10.1016/j.jacc.2024.10.067. Epub 2024 Oct 30. PubMed 39480380 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2029, 35 months after the start.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 35 months is close to that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Apr 8, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2036
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 1 site removed
Show 12 added (12 United States)
  • Banner Health · Phoenix, United States
  • Honor Health · Scottsdale, United States
  • Sutter Health/ California Pacific Medical Center · San Francisco, United States
  • Kaiser Permanente San Francisco · San Francisco, United States
  • Ascension Via Christi Hospital · Wichita, United States
  • Henry Ford Hospital · Detriot, United States
  • Minneapolis Heart Institute · Minneapolis, United States
  • Mayo Clinic · Rochester, United States
  • The Christ Hospital · Cincinnati, United States
  • Oregon Health and Science Unversity · Portland, United States
  • Medical University of South Carolina · Charleston, United States
  • Intermountain Medical Center · Murray, United States
Show 1 removed
  • Minneapolis Heart Institute Foundation · Minneapolis, United States
Nov 10, 2026
Enrollment
730→520
Nov 10, 2026
Interventions
Changed Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne System→Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System. Arm changed Randomized cohort VDyne TTVR→Randomized cohort VDyne TriNova TTVR
Nov 10, 2026
Primary outcomes
2 time frame changed, 4 description edited
What changed in the outcomes
  • Time frameChange in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)12 months post procedure → 12 months post-procedure
  • Time frameChange in Quality of Life (QOL) as measured by New York Heart Association (NYHA)12 months post procedure → 12 months post-procedure
  • DescriptionChange in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ): how it is measured was reworded
  • DescriptionChange in Quality of Life (QOL) as measured by New York Heart Association (NYHA): how it is measured was reworded
  • DescriptionComposite of all-cause mortality, heart failure hospitalization, or non-elective tricuspid valve reintervention: how it is measured was reworded
  • DescriptionComposite of major adverse events (MAEs): how it is measured was reworded
Nov 10, 2026
Secondary outcomes
2 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameChange in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)At 12 months and 24 months → 12 months post-procedure
  • Time frameChange in Quality of Life (QOL) as measured by New York Heart Association (NYHA)12 months → 12 months post-procedure
  • DescriptionChange in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ): how it is measured was reworded
Nov 10, 2026
Title
VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    12 sites added, 1 site removed
    Show 12 added (12 United States)
    • Banner Health · Phoenix, United States
    • Honor Health · Scottsdale, United States
    • Sutter Health/ California Pacific Medical Center · San Francisco, United States
    • Kaiser Permanente San Francisco · San Francisco, United States
    • Ascension Via Christi Hospital · Wichita, United States
    • Henry Ford Hospital · Detriot, United States
    • Minneapolis Heart Institute · Minneapolis, United States
    • Mayo Clinic · Rochester, United States
    • The Christ Hospital · Cincinnati, United States
    • Oregon Health and Science Unversity · Portland, United States
    • Medical University of South Carolina · Charleston, United States
    • Intermountain Medical Center · Murray, United States
    Show 1 removed
    • Minneapolis Heart Institute Foundation · Minneapolis, United States
    Enrollment 730→520
    Primary outcomes 2 time frame changed, 4 description edited
    What changed in the outcomes
    • Time frameChange in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)12 months post procedure → 12 months post-procedure
    • Time frameChange in Quality of Life (QOL) as measured by New York Heart Association (NYHA)12 months post procedure → 12 months post-procedure
    • DescriptionChange in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ): how it is measured was reworded
    • DescriptionChange in Quality of Life (QOL) as measured by New York Heart Association (NYHA): how it is measured was reworded
    • DescriptionComposite of all-cause mortality, heart failure hospitalization, or non-elective tricuspid valve reintervention: how it is measured was reworded
    • DescriptionComposite of major adverse events (MAEs): how it is measured was reworded
    Secondary outcomes 2 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameChange in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)At 12 months and 24 months → 12 months post-procedure
    • Time frameChange in Quality of Life (QOL) as measured by New York Heart Association (NYHA)12 months → 12 months post-procedure
    • DescriptionChange in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ): how it is measured was reworded
    Interventions Changed Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne System→Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System. Arm changed Randomized cohort VDyne TTVR→Randomized cohort VDyne TriNova TTVR
    Title VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)
    + 3 other changes: verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07516444
Lead sponsor
VDyne, Inc.
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Jul 28, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jun 2036 (estimated)
Last update
Nov 10, 2026

Study contacts

Vinny Podichetty
Contact
vpodichetty@vdyne.com
763-777-5969
Jeya Satheesh
Contact
jsatheesh@vdyne.com
952-686-8158
Susheel Kodali, MD
study chair · NYU Langone Health
Brian O'Neill, MD
principal investigator · Henry Ford Health System
Nadira Hamid, MD
principal investigator · Minneapolis Heart Institute
Vinod Thourani, MD
principal investigator · Piedmont Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion